Study S002118

The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05078255
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: TRIPLE
Status: COMPLETED
Enrollment: 61
Start: 2022-01-27
Primary completion: 2025-01-06
Lead sponsor: Asger Lund, MD
Conditions: Type 2 Diabetes; Obesity
Interventions: DRUG:Semaglutide 1.34 MG/ML [Ozempic]; DRUG:Glucose-dependent insulinotropic polypeptide (GIP); OTHER:Semaglutide 1.34 mg/ml placebo; OTHER:GIP placebo
Results posted: FALSE

Registered primary outcomes

Mean glucose levels (assessed by blinded continuous glucose monitoring (CGM)) [14-day mean glucose levels during the last 14 days of the intervention period as compared to 14-day mean glucose levels during the last 14 days of the run-in period.]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010858	Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial. Helsted MM, The lancet. Diabetes & endocrinology	2026	Randomized trial	PMID 42173109 DOI	cites ClinicalTrials.gov:NCT05078255; registry reference DERIVED:42173109
R0016004	Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial. Helsted MM, BMJ open	2023	Protocol	PMID 36849212 DOI	cites ClinicalTrials.gov:NCT05078255; registry reference DERIVED:36849212